Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.15 USD
-1.39 (-1.92%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $71.17 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.15 USD
-1.39 (-1.92%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $71.17 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.
Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
What's in the Cards for Universal Health (UHS) in Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
Henry Schein (HSIC) Stock Moves -0.78%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed at $78.81 in the latest trading session, marking a -0.78% move from the prior day.
Henry Schein (HSIC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Henry Schein (HSIC) closed at $81.10, marking a +0.25% move from the previous day.
Henry Schein (HSIC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $80.90, moving +1.2% from the previous trading session.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.
Henry Schein (HSIC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Henry Schein (HSIC) closed at $78.90, marking a -1.02% move from the previous day.
Henry Schein (HSIC) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $77.89, moving -0.17% from the previous trading session.
Henry Schein (HSIC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed at $76.01 in the latest trading session, marking a +0.62% move from the prior day.
Why Is Henry Schein (HSIC) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $75.26, moving -0.15% from the previous trading session.
Here's Why Investors Should Retain Henry Schein (HSIC) for Now
by Zacks Equity Research
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
Henry Schein (HSIC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -2.42% and 1.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Henry Schein (HSIC)
by Zacks Equity Research
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4% and 3.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $80.01, moving -0.58% from the previous trading session.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.